NYSEAMERICAN:OCXOncoCyte Stock Price, Forecast & News

$2.73

+0.03 (+1.11 %)

(As of 05/27/2020 04:00 PM ET)

Add

Compare

Today's Range

$2.61

Now: $2.73▼

$2.76

50-Day Range N/A

52-Week Range

$1.50

Now: $2.73▼

$4.64

Volume132,519 shs

Average Volume284,812 shs

Market Capitalization$183.51 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
OncoCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.38, OncoCyte has a potential upside of 170.1% from its current price of $2.73.
Amount of Analyst Coverage
OncoCyte has only been the subject of 1 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
OncoCyte has received 162 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
OncoCyte has received 131 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
OncoCyte has received 55.29% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote “Outperform” if you believe OCX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
OncoCyte does not currently pay a dividend.
Dividend Growth
OncoCyte does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OncoCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,413,508.00 in company stock and sold $0.00 in company stock.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

1.86 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNYSEAMERICAN:OCX

Previous SymbolAMEX:OCX

CUSIPN/A

CIK1642380

Webwww.oncocyte.com

Phone(510) 775-0515

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees12

Outstanding Shares67,218,000

Market Cap$183.51 million

Next Earnings Date8/12/2020 (Estimated)

OptionableNot Optionable

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of OncoCyte?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OncoCyte.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for OncoCyte.

How were OncoCyte's earnings last quarter?

OncoCyte Corp (NYSEAMERICAN:OCX) issued its quarterly earnings data on Tuesday, May, 12th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.02. The biotechnology company earned $0.02 million during the quarter. View OncoCyte's earnings history.

What price target have analysts set for OCX?

2 analysts have issued 1-year target prices for OncoCyte's stock. Their forecasts range from $7.00 to $7.75. On average, they expect OncoCyte's stock price to reach $7.38 in the next year. This suggests a possible upside of 170.1% from the stock's current price. View analysts' price targets for OncoCyte.

Has OncoCyte been receiving favorable news coverage?

Media headlines about OCX stock have been trending somewhat positive on Wednesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OncoCyte earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutOncoCyte.

Who are some of OncoCyte's key competitors?

Some companies that are related to OncoCyte include Bellus Health (BLU), CEL-SCI (CVM), Oxford BioMedica (OXB), Cel-Sci (CVM), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), ProMetic Life Sciences (PLI), IMV (IMV), Medicenna Therapeutics (MDNA) and Emblem (EMC). View all competitors.

What other stocks do shareholders of OncoCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include BioTime (BTX), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Geron (GERN), Anavex Life Sciences (AVXL), Novocure (NVCR), Amicus Therapeutics (FOLD), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO) and Ovid Therapeutics (OVID).

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:

Mr. William Annett, Pres, CEO & Director (Age 65)
Mr. Mitchell S. Levine, Chief Financial Officer
Dr. Lyndal K. Hesterberg, Chief Scientific Officer
Mr. Albert P. Parker II, Chief Operating Officer
Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.51%), State Street Corp (0.69%), P.A.W. Capital Corp (0.56%), Geode Capital Management LLC (0.52%), Phoenix Holdings Ltd. (0.39%) and Penbrook Management LLC (0.35%). Company insiders that own OncoCyte stock include Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews and Thomas Alex Vetter. View institutional ownership trends for OncoCyte.

Which major investors are selling OncoCyte stock?

OCX stock was sold by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc., Morgan Stanley, BlackRock Inc., UBS Group AG, and State Street Corp. View insider buying and selling activity for OncoCyte.

Which major investors are buying OncoCyte stock?

OCX stock was bought by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., P.A.W. Capital Corp, Penbrook Management LLC, Nuveen Asset Management LLC, Perkins Capital Management Inc., Geode Capital Management LLC, Bank of New York Mellon Corp, and ETF Managers Group LLC. Company insiders that have bought OncoCyte stock in the last two years include Andrew Arno, Broadwood Partners, LP, Mitchell S Levine, Ronald Asbury Andrews, and Thomas Alex Vetter. View insider buying and selling activity for OncoCyte.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $2.73.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $183.51 million. OncoCyte employs 12 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.

This page was last updated on 5/27/2020 by MarketBeat.com Staff